Karyopharm Therapeutics Inc (OQ:KPTI)

Feb 22, 2024 06:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
-- Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET --
Feb 01, 2024 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,850 restricted stock units (RSUs) to seven newly-hired employees. These RSU awards were granted as of January 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 08, 2024 07:30 am ET
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer and Myelofibrosis – 
Jan 03, 2024 06:00 am ET
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 42nd Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 10 at 2:15 p.m. PT, followed by a question-and-answer breakout session at 2:35 p.m. PT.
Jan 02, 2024 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 2, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 42,000 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of December 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 10, 2023 07:15 pm ET
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR
Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification
Dec 01, 2023 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 15,700 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of November 30, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 08, 2023 03:05 pm ET
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:
Nov 06, 2023 06:00 am ET
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgr
Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival  (OS) Regardless of Mismatched Repair Status (MMR)
Nov 02, 2023 09:20 am ET
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation
Nov 02, 2023 07:30 am ET
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million –
Oct 30, 2023 08:00 am ET
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Mul
—  Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with Selinexor  in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies –
Oct 26, 2023 07:00 am ET
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
-- Conference Call Scheduled for Thursday, November 2, 2023, at 8:00 a.m. ET --
Oct 02, 2023 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Oct. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 83,850 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of September 30, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 26, 2023 07:00 am ET
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
NEWTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece. In addition, exploratory subgroup analyses from the SIENDO Study in patients with advanced or recurrent TP53 wild-type endometrial cancer will be presented in an oral session, "Abstract Session: Best Oral Session – En
Aug 02, 2023 07:30 am ET
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million –
Aug 01, 2023 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,350 restricted stock units (RSUs) to 4 newly-hired employees. These RSU awards were granted as of July 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 26, 2023 07:00 am ET
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
-- Conference Call Scheduled for Wednesday, August 2, 2023, at 8:00 a.m. ET --
Jul 25, 2023 03:00 pm ET
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Signal of PFS Improvement in SIENDO for Selinexor-Treated Patients was Observed Only in Subgroup Who are TP53 Wild-Type with a Median Progression-Free Survival of 27.4 Months 
Jul 19, 2023 08:00 am ET
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25t
-  Data Provide Further Support for Company's Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer -
Jul 18, 2023 09:31 am ET
Thinking about buying stock in Ballard Power Systems, Apellis Pharmaceuticals, Mind Medicine, Nio Inc, or Karyopharm Therapeutics?
NEW YORK, July 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLDP, APLS, MNMD, NIO, and KPTI.
Jul 17, 2023 04:05 pm ET
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
– Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis –
Jul 05, 2023 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., July 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 171,400 restricted stock units (RSUs) to 11 newly-hired employees. These RSU awards were granted as of June 30, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 28, 2023 08:00 am ET
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
Phase 3 Study is Supported by Previously Presented Phase 1 Study Results, Including a 78.6% SVR35 and 58.3% TSS50 in Intent to Treat Patients at Week 24 at the 60mg Dose
Jun 01, 2023 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 44,600 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of May 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jun 01, 2023 07:00 am ET
Karyopharm to Participate at the Jefferies Healthcare Conference
NEWTON, Mass., June 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Healthcare Conference in a fireside chat on Thursday, June 8, 2023 at 10:00 a.m. ET in New York, NY.
May 23, 2023 04:05 pm ET
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
NEWTON, Mass., May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany.
May 04, 2023 07:45 am ET
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved First Quarter 2023 Total Revenues of $38.7 Million, including XPOVIO® (selinexor) Net Product Revenue of $28.3 Million, Adversely Impacted by Increased Utilization of Patient Assistant Programs (PAP) and Higher Gross to Net; YoY Growth in Total Demand1–
May 01, 2023 04:10 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., May 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,600 restricted stock units (RSUs) to four newly-hired employees, with a grant date of April 30, 2023. Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the applicable employee's employment commencement date.
May 01, 2023 04:05 pm ET
Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
-- Conference Call Scheduled for Thursday, May 4, 2023, at 8:00 a.m. ET --
Apr 18, 2023 01:30 pm ET
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
–  At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in Intent to Treat Population –
Apr 14, 2023 12:00 pm ET
Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th
 – Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2023 from All Patients Enrolled in the Phase 1 Study –
Apr 03, 2023 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., April 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 221,900 restricted stock units (RSUs) to thirteen newly-hired employees. These RSU awards were granted as of March 31, 2023. Each RSU award will vest over three years, with 33 1/3% percent of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the applicable employee's employment commencement date.
Mar 14, 2023 05:36 pm ET
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023
NEWTON, Mass., March 14, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida.
Mar 08, 2023 06:00 am ET
Karyopharm to Participate at Barclays Global Healthcare Conference
NEWTON, Mass., March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Barclays Global Healthcare Conference in a fireside chat on Wednesday, March 15 at 4:35 p.m. ET.
Feb 09, 2023 06:00 am ET
Karyopharm to Present at SVB Securities Global Biopharma Conference
NEWTON, Mass., Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the virtual SVB Securities Global Biopharma Conference in a fireside chat on Thursday, February 16 at 11:20 a.m. ET.
Feb 08, 2023 06:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023
-- Conference Call Scheduled for Wednesday, February 15, 2023, at 8:00 a.m. ET --
Feb 01, 2023 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 113,250 restricted stock units (RSUs) to ten newly-hired employees. These RSU awards were granted as of January 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 09, 2023 07:00 am ET
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives
– Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $157.7 Million and $120.4 Million, Respectively, Meeting Company's Guidance –
Jan 04, 2023 06:00 am ET
Karyopharm to Present at 41st Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 4, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 41st Annual J.P. Morgan Healthcare Conference in a podium presentation on Wednesday, January 11 at 10:30 a.m. PT, followed by a question-and-answer breakout session at 10:50 a.m. PT.
Jan 03, 2023 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 24,300 shares of Karyopharm's common stock and an aggregate of 16,600 restricted stock units (RSUs) to four newly-hired employees. These equity awards were granted as of December 30, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm
Dec 12, 2022 06:00 am ET
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022
– A 92% SVR35 and a 67% TSS50 were Observed in the Efficacy Evaluable Patients at Week 24 –
Dec 05, 2022 07:30 am ET
Karyopharm Announces $165 Million Private Placement
NEWTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with certain institutional investors for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses. The private placement was led by Avidity Partners, with participation by existing stockholders and new investors including Adage Capital Partners LP, Armistice Capital, Health
Dec 05, 2022 07:30 am ET
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis
– Key Opinion Leaders to Review Highlights from Updated Phase 1 Data to be Presented at ASH 2022 at Company Sponsored Event on Monday, December 12 at 8:30 AM ET –
Dec 01, 2022 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 6,100 shares of Karyopharm's common stock and an aggregate of 4,200 restricted stock units (RSUs) to two newly-hired employees. These equity awards were granted as of November 30, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in
Nov 08, 2022 06:00 am ET
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., Nov. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in November:
Nov 03, 2022 04:05 pm ET
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved Third Quarter 2022 Total Revenue of $36.1 Million, Including XPOVIO® (selinexor) Net Product Revenue of $32.0 Million, a 20 % Increase Over Third Quarter 2021–
Nov 03, 2022 09:18 am ET
Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022
–  Encouraging Data Observed in Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Activity Across Three Key Efficacy Endpoints of Spleen Volume Reduction, Symptom Improvement, and Hemoglobin Stabilization, with a Generally Manageable Tolerability Profile and No Dose Limiting Toxicities–
Nov 01, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted stock options to purchase an aggregate of 23,200 shares of Karyopharm's common stock and an aggregate of 16,000 restricted stock units (RSUs) to seven newly-hired employees. These equity awards were granted as of October 31, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm
Nov 01, 2022 07:08 am ET
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /CNW/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the U. S. Food and Drug Administration (FDA) in May 2022. Karyopharm is currently evaluating selinexor, a fir
Nov 01, 2022 07:08 am ET
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the U. S. Food and Drug Administration (FDA) in May 2022. Karyopharm is currently evaluating selinexor
Oct 31, 2022 04:35 pm ET
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Oct. 31, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the U. S. Food and Drug Administration (FDA) in May 2022. Karyopharm is currently evaluating selinexor
Oct 20, 2022 04:05 pm ET
Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022
-- Conference Call Scheduled for Thursday, November 3, 2022, at 4:30 p.m. ET --
Oct 03, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 3, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on September 30, 2022 (the Grant Date), the Company granted a stock option to purchase 1,200 shares of Karyopharm's common stock and an award of 800 restricted stock units (RSUs) to one newly-hired employee. The stock option has an exercise price of $5.46 per share, the closing price of Karyopharm's common stock on the Grant Date. The stock option will vest over four years, with 25% of the total number of sh
Sep 07, 2022 07:00 am ET
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
Sep 01, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2022  /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 40,800 shares of Karyopharm's common stock and an aggregate of 28,000 restricted stock units (RSUs) to eight newly-hired employees.
Aug 04, 2022 07:30 am ET
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021;
Aug 02, 2022 07:00 am ET
Karyopharm to Participate at the 2022 Wedbush Pacgrow Healthcare Conference
NEWTON, Mass., Aug. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 Wedbush Pacgrow Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Tuesday, August 9, 2022 at 4:05 p.m. ET.
Aug 01, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 26,100 shares of Karyopharm's common stock and an aggregate of 18,000 restricted stock units (RSUs) to eight newly-hired employees. These equity awards were granted as of July 29, 2022 (the Grant Date) pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering int
Jul 28, 2022 07:09 am ET
Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022
-- Conference Call Scheduled for Thursday, August 4, 2022, at 8:00 a.m. ET --
Jul 21, 2022 09:13 am ET
Jul 21, 2022 09:13 am ET
Jul 21, 2022 07:00 am ET
Jul 20, 2022 07:00 am ET
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic Syndromes
– FDA Fast Track Designation and European Commission Orphan Medicinal Product Designation Underscore the Significant Need for New Treatment Options for MDS –
Jun 01, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 136,700 shares of Karyopharm's common stock and an aggregate of 90,700 restricted stock units (RSUs) to 18 newly-hired employees. These equity awards were granted as of May 31, 2022 (the Grant Date) pursuant to the Company's 2022 Inducement Stock Incentive Plan, as inducements material to the new employees entering into employment wi
Jun 01, 2022 07:00 am ET
Karyopharm to Participate at the Jefferies Healthcare Conference
NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m. ET in New York, NY.
May 26, 2022 05:08 pm ET
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting
– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable Patients Demonstrating ≥35% Spleen Volume Reduction (SVR 35) at Week 12 –
May 25, 2022 07:00 am ET
The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study
- Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma -
May 20, 2022 10:39 am ET
May 20, 2022 10:39 am ET
May 20, 2022 08:45 am ET
May 12, 2022 11:00 am ET
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
NEWTON, Mass., May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis has been selected for a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress taking place June 9-12, 2022, in Vienna, Austria. The data are also being presented in a poster session at the American Society of Clinical Oncol
May 10, 2022 07:00 am ET
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY.
May 05, 2022 07:00 am ET
Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners –
May 02, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., May 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Reshma Rangwala, Executive Vice President, Chief Medical Officer, the Compensation Committee of Karyopharm's Board of Directors (the "Compensation Committee") granted a stock option to purchase 100,000 shares of Karyopharm's common stock and 65,000 restricted stock units ("RSUs") to Dr. Rangwala, with a grant date of April 29, 2022. 
Apr 28, 2022 07:00 am ET
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
-- Conference Call Scheduled for Thursday, May 5, 2022, at 8:30 a.m. ET --
Apr 27, 2022 10:01 am ET
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
NEWTON, Mass., April 27, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts highlighting selinexor clinical research have been selected for presentation, including one oral presentation, at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3-7, 2022, in Chicago.
Apr 07, 2022 07:00 am ET
Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference
NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Thursday, April 14, 2022 at 9:30 a.m. ET.
Apr 01, 2022 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., April 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 58,600 shares of Karyopharm's common stock and an aggregate of 36,900 restricted stock units (RSUs) to six newly-hired employees. These equity awards were granted as of March 31, 2022 (the Grant Date) pursuant to the Company's 2022 Inducement Stock Incentive Plan, as inducements material to the new employees entering into employment
Mar 29, 2022 08:00 am ET
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy -
Mar 16, 2022 07:00 am ET
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
Study Results to be Presented at the European Society of Medical Oncology's Virtual Plenary and the Society for Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
Mar 14, 2022 07:00 am ET
Karyopharm Names New Head of Investor Relations
– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations –
Mar 09, 2022 06:00 am ET
Karyopharm to Participate at the Barclays Global Healthcare Conference
NEWTON, Mass., March 9, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference. The conference is being held in Miami, Florida and the fireside chat will take place on Wednesday, March 16, 2022 at 10:15 a.m. ET.
Mar 01, 2022 03:05 pm ET
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
NEWTON, Mass., March 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its previously planned supplemental New Drug Application (sNDA) submission based on the data from the Phase 3 SIENDO study evaluating selinexor as a front-line maintenance therapy following chemotherapy in patients with advanced or recurrent endometrial cancer.
Feb 28, 2022 03:56 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 168,500 shares of Karyopharm's common stock and an aggregate of 112,200 restricted stock units (RSUs) to nine newly-hired employees. These equity awards were granted as of February 28, 2022 (the Grant Date) pursuant to the Company's 2022 Inducement Stock Incentive Plan, as inducements material to the new employees entering into empl
Feb 22, 2022 06:00 am ET
Karyopharm Announces Changes to Its Clinical Leadership Team
NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory c
Feb 18, 2022 10:50 am ET
Thinking about buying stock in Creative Medical Technology, Nu Holdings, Barrick Gold, Opendoor Technologies, or Karyopharm Therapeutics?
NEW YORK, Feb. 18, 2022 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for CELZ, NU, GOLD, OPEN, and KPTI.
Feb 11, 2022 06:00 am ET
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Friday, February 18, 2022 at 1:40 p.m. ET.
Feb 08, 2022 06:35 am ET
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor) and provided an overview of its key clinical development programs.
Feb 08, 2022 06:30 am ET
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 Selinexor In ENDOmetrial Cancer (SIENDO/ENGOT-EN5/GOG-3055) study (n=263) evaluating the efficacy and safety of front-line maintenance therapy using selinexor, an oral medication, in patients with advanced or recurrent endometrial cancer. The SIENDO study met its primary endpoint of a statistically significant improvement in median progression-free survival (PFS) compare
Feb 02, 2022 06:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022
NEWTON, Mass., Feb. 2, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, February 8, 2022, to discuss the financial results and other company updates.
Feb 01, 2022 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 124,500 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of January 31, 2022. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 21, 2022 06:00 am ET
Karyopharm to Present at B. Riley Securities Oncology Investor Conference
NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 28 at 9:30 a.m. ET.
Jan 10, 2022 06:05 am ET
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the Company's commercial strategy and operations, including the continued commercialization of XPOVIO® (selinexor). Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations. 
Jan 10, 2022 06:00 am ET
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company's first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.
Jan 04, 2022 06:00 am ET
Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 4, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present at the 40th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Tuesday, January 11 at 3:45 p.m. ET, followed by a question and answer breakout session at 4:05 p.m. ET.
Jan 03, 2022 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 5,600 shares of Karyopharm's common stock to 2 newly-hired employees, with a grant date of December 31, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 21, 2021 07:51 am ET
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
NEWTON, Mass. and FLORENCE, Italy, Dec. 21, 2021 /CNW/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held, leading international pharmaceutical company, today announced their entry into an exclusive licensing agreement whereby Menarini will commercialize NEXPOVIO, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in Europe and other key global territories.
Dec 21, 2021 07:51 am ET
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
NEWTON, Mass. and FLORENCE, Italy, Dec. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held, leading international pharmaceutical company, today announced their entry into an exclusive licensing agreement whereby Menarini will commercialize NEXPOVIO, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in Europe and other key global territories.
Dec 21, 2021 06:30 am ET
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
NEWTON, Mass. and FLORENCE, Italy, Dec. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held, leading international pharmaceutical company, today announced their entry into an exclusive licensing agreement whereby Menarini will commercialize NEXPOVIO, Karyopharm's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in Europe and other key global territories.
Dec 17, 2021 07:37 am ET
Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
NEWTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner, Antengene Corporation (Antengene), has been granted conditional approval for marketing by the China National Medical Products Administration (NMPA) for XPOVIO® (selinexor), a first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in combination with dexamethasone in patients with relapsed or refractory multiple myeloma who have received prior therapies and whose disease
Dec 11, 2021 11:00 am ET
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
NEWTON, Mass., Dec. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with myelofibrosis (MF) previously treated with JAK inhibition.  These updated results were presented at the American Society of Hematology (ASH) 2021 Annual Meeting and Expositi
Dec 06, 2021 03:05 pm ET
Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors
NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021. Dr. Honig brings to Karyopharm over 30 years of drug development and regulatory sciences experience from past leadership roles with Pfizer, Merck and the U.S. Food and Drug Administration (FDA). Dr. Honig replaces Mikael Dolsten, MD, PhD, who has transitioned off the Board due to competing professional demands, effec
Dec 06, 2021 06:00 am ET
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis
NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in a new Phase 2 study evaluating oral selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a monotherapy versus physician's choice in patients with myelofibrosis (MF) previously treated with a JAK 1/2 inhibitor (XPORT-MF-035; NCT04562870).
Dec 02, 2021 06:00 am ET
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
NEWTON, Mass., Dec. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the completion of patient recruitment in the Phase 3 SIENDO study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer.
Dec 01, 2021 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 68,900 shares of Karyopharm's common stock to 13 newly-hired employees, with a grant date of November 30, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 01, 2021 06:00 am ET
Karyopharm to Host Virtual Investor Day on December 8, 2021
NEWTON, Mass., Dec. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a virtual Investor Day on Wednesday, December 8, 2021 from 10:00 a.m. to 12:30 p.m. ET. Karyopharm's executive management team will be joined by six recognized thought leaders in multiple myeloma, gynecological malignancies, myelodysplastic syndromes and myelofibrosis, including:
Nov 11, 2021 06:00 am ET
Karyopharm to Participate at Jefferies London Healthcare Conference
NEWTON, Mass., Nov. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the Jefferies London Healthcare Conference. The fireside chat will be made available for on-demand listening beginning Thursday, November 18, 2021 at 3:00 a.m. Eastern Time.
Nov 04, 2021 10:30 am ET
Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and Exposition
NEWTON, Mass., Nov. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a Phase 2 study evaluating selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with myelofibrosis (MF) previously treated with JAK inhibition has been selected for an oral presentation at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition in Atlanta, GA on December 11-14, 2021.
Nov 03, 2021 07:00 am ET
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business Highlights
NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2021 and provided business highlights.
Nov 01, 2021 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Nov. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 171,300 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of October 29, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 27, 2021 07:00 am ET
Karyopharm to Report Third Quarter 2021 Financial Results on November 3, 2021
NEWTON, Mass., Oct. 27, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Wednesday, November 3, 2021, to discuss the financial results and other company updates.
Oct 21, 2021 08:00 am ET
Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic Syndrome
NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patient in the Phase 2 expansion of an ongoing open-label Phase 1/2 study investigating eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) compound, as a single-agent or in combination with approved and investigational agents in patients with several types of hematologic and solid tumor cancers (KCP-8602-801; NCT02649790). The Phase 2 expansion is designed to evaluate eltane
Oct 01, 2021 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Oct. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 147,300 shares of Karyopharm's common stock to 21 newly-hired employees, with a grant date of September 30, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 07, 2021 07:00 am ET
Karyopharm Announces Upcoming Virtual Investor Conference Participation
NEWTON, Mass., Sept. 7, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate in the following virtual investor conferences in September:
Sep 01, 2021 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Eleonora Goldberg, Senior Vice President of Global Medical & Scientific Affairs,  the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm's common stock to Dr. Goldberg, with a grant date of August 31, 2021. The stock option was granted as an inducement material to Dr. Goldberg entering into employment
Aug 05, 2021 07:00 am ET
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
NEWTON, Mass., Aug. 5, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended June 30, 2021.
Aug 03, 2021 07:00 am ET
Karyopharm Announces Upcoming Virtual Investor Conference Participation
NEWTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer, will participate on a speaker panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference titled, "Building Back a Better Commercial Infrastructure – Selling in COVID Times" and participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference. Details regarding these upcoming virtual investor conferences are below.
Aug 02, 2021 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 74,600 shares of Karyopharm's common stock to 11 newly-hired employees, with a grant date of July 30, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 29, 2021 07:00 am ET
Karyopharm to Report Second Quarter 2021 Financial Results on August 5, 2021
NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, August 5, 2021, to discuss the financial results and other company updates.
Jul 28, 2021 07:00 am ET
Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis
NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis. These company-sponsored studies follow encouraging results from preclinical r
Jul 01, 2021 08:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., July 1, 2021  /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that in connection with the hiring of Ms. Sohanya Cheng, Senior Vice President, Sales and Commercial Operations, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 125,000 shares of Karyopharm's common stock to Ms. Cheng, with a grant date of June 30, 2021. The stock option was granted as an inducement material to Ms. Cheng's entering into employment with Karyopharm
Jun 24, 2021 07:00 am ET
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million
NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of its royalty agreement with entities managed by HealthCare Royalty Management, LLC (HCR) for up to $100 million in new financing to support the ongoing development and commercialization of XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and for the clinical development of Karyopharm's other programs, including eltanexor. XPOVIO is
Jun 09, 2021 07:00 am ET
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstracts have been selected for virtual presentation, including one oral presentation, at the upcoming European Hematology Association (EHA) 2021 Virtual Congress taking place June 9-17, 2021.
Jun 08, 2021 08:00 pm ET
Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%--
Jun 08, 2021 04:01 pm ET
Karyopharm Announces Key Changes to Its Commercial Leadership Team
NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management changes to its commercial organization, including the appointment of Sohanya Cheng, MBA, as Senior Vice President of Sales and Commercial Operations. Payman Darouian, PharmD, Senior Vice President of Marketing will lead all marketing activities for Karyopharm's lead product, XPOVIO® (selinexor). In addition, John Demaree, Chief Commercial Officer, and Perry Monaco, Senior Vice President of Sales, wi
Feb 17, 2021 03:05 pm ET
Karyopharm Announces Upcoming Virtual Investor Conference Participation
NEWTON, Mass., Feb. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at SVB Leerink's 10th Annual Global Healthcare Conference and at the Barclays Global Healthcare Conference.  Details regarding these upcoming virtual investor conferences are below.
Feb 12, 2021 10:50 pm ET
KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).
Feb 11, 2021 06:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), regulatory progress in Europe, and provided an overview of its key clinical development programs.
Feb 04, 2021 08:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 11, 2021. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, February 11, 2021, to discuss the financial results and other company updates.
Feb 04, 2021 06:00 am ET
Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israel's regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO are a) in combinat
Feb 01, 2021 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Feb. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 165,500 shares of Karyopharm's common stock to 31 newly-hired employees, with a grant date of January 29, 2021.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 29, 2021 09:50 pm ET
KARYOPHARM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI
NEW ORLEANS, Jan. 29, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).  
Jan 29, 2021 07:38 am ET
Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for NEXPOVIO® (selinexor) in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory
Jan 11, 2021 07:00 am ET
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
NEWTON, Mass., Jan. 11, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2020 total revenue estimates including net product sales for XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, and provided additional updates on XPOVIO's commercial progress.
Jan 04, 2021 03:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 50,500 shares of Karyopharm's common stock to 12 newly-hired employees, with a grant date of December 31, 2020. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jan 04, 2021 06:00 am ET
Karyopharm to Present at 39th Annual J.P. Morgan Healthcare Conference
NEWTON, Mass., Jan. 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Monday, January 11 at 4:30 p.m. ET, followed by a question and answer breakout session at 4:50 p.m. ET.
Jan 03, 2021 06:00 pm ET
Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
SHANGHAI and HONG KONG, Jan. 3, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that it has submitted a New Drug Application (NDA) with Orphan Drug Designation (ODD) to the South Korean Ministry of Food and Drug Safety (MFDS) for ATG-010 (selinexor, XPOVIO®) in combination with low dose dexamethasone for the treatment of adult patients with relapsed/refractory mult
Dec 20, 2020 06:00 pm ET
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 20, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for oral XPOVIO® (selinexor, ATG-010), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. This indication was app
Dec 18, 2020 10:50 pm ET
KARYOPHARM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Karyopharm Therapeutics Inc. - KPTI
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Karyopharm Therapeutics Inc. (NasdaqGS: KPTI).
Dec 18, 2020 10:30 am ET
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO was previously approved under the FDA's Accelerated Approval Program for the treat
Dec 15, 2020 06:00 am ET
Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel.  Mr. Mano brings over 15 years of legal experience and previously served as Counsel, Business Development at Biogen Inc.
Dec 11, 2020 10:08 am ET
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for previously treated multiple myeloma. The XPOVIO regimens added to the NCCN guidelines, include: (i) selinexor / bortezomib / dexamethasone (once-weekly) (SVd); (ii) selinexor / daratumumab / dexamethasone (SDd); and (iii) selin
Dec 07, 2020 03:05 pm ET
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced an oral presentation highlighting data related to XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, was presented at the American Society of Hematology (ASH) 2020 Annual Meeting taking place virtually December 5-8, 2020. The presentation featured new data from a randomized, investigator-sponsored Phase 2 study evaluating combination chemotherapy with or
Dec 07, 2020 12:30 pm ET
Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that over twenty presentations related to XPOVIO® (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, were presented at the American Society of Hematology (ASH) 2020 Annual Meeting taking place virtually December 5-8, 2020. These presentations included:
Dec 01, 2020 03:05 pm ET
Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will host a virtual investor and analyst event to discuss the Company's pipeline of clinical programs and highlights from the data presentations being given at the American Society of Hematology (ASH) 2020 Annual Meeting. This Karyopharm-sponsored event is scheduled for Tuesday, December 8, 2020 from 1:00 - 2:30 p.m. ET.
Dec 01, 2020 06:00 am ET
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointments of Chen Schor, MBA, to its Board of Directors and Stephen Mitchener, PharmD, as Chief Business Officer. Mr. Schor currently serves as President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class therapies for cancer and other diseases. Dr. Mitchener joins Karyopharm from Axcella Healthcare, a cl
Nov 25, 2020 06:00 am ET
Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the S
NEWTON, Mass., Nov. 25, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study, the Data and Safety Monitoring Board (DSMB) has recommended that the study should continue, as previously planned, without the need for adding additional patients to the trial or amending the study protocol.
Nov 20, 2020 09:30 am ET
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
NEWTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with liposarcoma at the Connective Tissue Oncology Society 2020 Annual Meeting (CTOS 2020). As previously reported, the SEAL study met its primary endpoint of a statistically significant increase i
Nov 12, 2020 06:06 pm ET
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
NEWTON, Mass., Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (Bortezomib, Selinexor and Dexamethasone) study evaluating XPOVIO in patients with relapsed or refractory multiple myeloma were published online in The Lancet. The BOSTON study evaluated once weekly XPOVIO, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, in combination with once weekly Velcade® (bortezomib) and low-dose dexamethason
Nov 10, 2020 06:00 am ET
Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference
NEWTON, Mass., Nov. 10, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 1:45 p.m. ET.
Nov 04, 2020 12:16 pm ET
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected for virtual presentation, including two oral presentations, at the upcoming American Society of Hematology (ASH) 2020 Annual Meeting taking place December 5-8, 2020. Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company's first in class, oral SINE compound, including: (i) updated data from the Pomalyst® (poma
Nov 03, 2020 07:00 am ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Nov. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 86,900 shares of Karyopharm's common stock to 13 newly-hired employees, with a grant date of October 30, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 02, 2020 03:05 pm ET
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended September 30, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
Nov 02, 2020 03:01 pm ET
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
NEWTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3 portion of the randomized, double blind, placebo controlled, cross-over, SEAL study evaluating single agent, oral XPOVIO® (selinexor) versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma. The SEAL study met its primary endpoint of a statistically significant increase in progression-free survival (PFS); hazard ratio=0.70; p=0.
Oct 26, 2020 07:00 am ET
Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020
NEWTON, Mass., Oct. 26, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2020 financial results on Monday, November 2, 2020. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 2, 2020, to discuss the financial results and other company updates.
Oct 20, 2020 10:00 am ET
Karyopharm Therapeutics Selects MediSpend's Transparency Solution
PORTSMOUTH, N.H., Oct. 20, 2020 /PRNewswire/ -- MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) selected MediSpend Transparency Solution to comply with state and federal transparency reporting regulations. MediSpend Transparency Solution is a SaaS-based solution that collects, remediates, validates, analyzes and reports transfers of value to comply with state, federal and global transparency laws and codes. Karyopharm Therapeutics was implemented and went live with MediSpend's Transparency Solution in October 2020.
Oct 19, 2020 04:01 pm ET
Replimune Appoints Tanya Lewis to the Board of Directors
Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2,...
Aug 04, 2020 07:00 am ET
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
NEWTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended June 30, 2020. In addition, Karyopharm highlighted select corporate milestones, including details regarding the ongoing U.S. commercialization of XPOVIO® (selinexor), and provided an overview of its key clinical development programs.
Aug 03, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 3, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 27,300 shares of Karyopharm's common stock to three newly-hired employees, with a grant date of July 31, 2020.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Jul 28, 2020 07:00 am ET
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
NEWTON, Mass., July 28, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) an innovation-driven pharmaceutical company, today announced that it will report second quarter 2020 financial results on Tuesday, August 4, 2020. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, August 4, 2020, to discuss the financial results and other company updates.
Jul 20, 2020 07:00 am ET
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Ther
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking approval for...
Jul 17, 2020 07:00 am ET
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy...
Jul 14, 2020 07:00 am ET
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced preliminary unaudited second quarter 2020 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of...
Jul 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 41,700 shares of...
Jun 24, 2020 07:00 am ET
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating XPOVIO in patients with relapsed or...
Jun 22, 2020 11:25 am ET
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of...
Jun 12, 2020 07:00 am ET
Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound,...
Jun 09, 2020 09:00 am ET
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients...
Jun 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of...
May 28, 2020 04:05 pm ET
Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- SVd Was Superior to Vd Across Key Secondary Efficacy Endpoints Including Overall Response Rate, Percent of Patients Achieving ≥VGPR and Median Duration of Response -- -- SVd Was Associated with Significantly Lower Rates and Severity of...
May 26, 2020 04:05 pm ET
Karyopharm to Participate at Jefferies Virtual Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on...
May 26, 2020 07:00 am ET
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to discuss detailed results from the pivotal, Phase 3 BOSTON study evaluating once-weekly XPOVIO®...
May 20, 2020 08:00 am ET
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOVIO®...
May 13, 2020 08:00 am ET
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19...
May 12, 2020 07:00 am ET
Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare...
May 05, 2020 07:00 am ET
Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today reported financial results for the quarter ended March 31, 2020. In addition, Karyopharm highlighted select corporate milestones, including details...
May 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 74,800 shares of...
Apr 30, 2020 01:03 pm ET
PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial
PROMETRIKA (www.prometrika.com), a leading clinical research organization, is collaborating with Karyopharm Therapeutics (Nasdaq:
Apr 29, 2020 01:58 pm ET
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the...
Apr 28, 2020 04:05 pm ET
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it will report first quarter 2020 financial results on Tuesday, May 5, 2020. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Tuesday, May...
Apr 22, 2020 09:08 am ET
Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19
BUDAPEST, Hungary, April 22, 2020 /PRNewswire/ -- Precision for Medicine, a pioneer in the design, development and execution of biomarker-informed clinical studies and complex data management, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to help conduct the first global randomized clinical trial for low dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19. 
Apr 20, 2020 07:00 am ET
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll...
Apr 07, 2020 07:00 am ET
Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor, marketed as XPOVIO®, is currently approved at...
Apr 01, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 161,500 shares of...
Mar 17, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyopharm’s common...
Mar 12, 2020 07:00 am ET
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy and...
Mar 09, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shares of...
Mar 06, 2020 04:05 pm ET
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase...
Mar 03, 2020 06:36 pm ET
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock  at a price to the...
Mar 02, 2020 04:01 pm ET
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also...
Mar 02, 2020 07:00 am ET
Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced positive top-line results from the randomized Phase 3 BOSTON study evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly...
Feb 28, 2020 07:00 am ET
Karyopharm Appoints Richard Paulson to its Board of Directors
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its Board of Directors. Mr. Paulson is currently Executive Vice President and Chief Executive Officer of...
Feb 19, 2020 08:00 am ET
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) seeking accelerated...
Feb 18, 2020 07:00 am ET
Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare...
Feb 13, 2020 07:00 am ET
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2019. In addition, Karyopharm highlighted select corporate milestones,...
Feb 11, 2020 07:00 am ET
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for the commercialization of XPOVIO®...
Feb 06, 2020 07:00 am ET
Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13, 2020. Karyopharm's management team will host a...
Feb 03, 2020 04:05 pm ET
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 shares of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.